Digital Ulcers Linked to More Severe Systemic Sclerosis PDF Print E-mail
Sunday, 23 January 2011 10:46
Digital ulcers are associated with more severe systemic sclerosis (SSc) disease, including skin and lung involvement, but not with pulmonary arterial hypertension (PAH) or scleroderma renal crisis (SRC), according to research published in the January issue of Arthritis Care & Research.

Sarit Khimdas, from the University of Western Ontario in London, Canada, and colleagues analyzed data from 938 patients with SSc who participated in the Canadian Scleroderma Research Group, which collects information from SSc patients annually. Data included the presence, position, and number of digital ulcers; complications; involvement of internal organs; skin score; and results from laboratory testing.

The investigators found that 8 percent of patients currently had a digital ulcer; 44 percent had had one in the past; and 53.1 percent had digital pitting scars. In limited cutaneous SSc and diffuse cutaneous SSc subsets, digital ulcers were associated with a higher disease burden, as evidenced by higher Rodnan skin scores, hand and finger scores, and worse hand function according to the Health Assessment Questionnaire score. Digital ulcers were also linked to longer disease duration, younger age at disease onset, interstitial lung disease, and topoisomerase I antibodies. No association was seen with sex, smoking, PAH, or SRC. In diffuse cutaneous SSc, digital ulcers were associated with reduced diffusing capacity for carbon monoxide and esophageal involvement.

"In conclusion, there are some associations with digital ulcers but a surprising lack of association between digital ulcers and other manifestations of structural vasculopathy, including PAH and SRC," the authors write.

Source: DoctorsLounge. Original article can be viewed here.
 
More articles :

» Mixed Connective Tissue Disease May Represent Subset of Systemic Scleroderma

Many patients with (MCTD) may represent a subset of Systemic , rather than a disease involving overlapping connective tissue disorders as is commonly believed, or a subset of Lupus as some have suggested over the years, Dr. Virginia Steen said at...

» Orphan Drug Status Granted For Revimmune In Treatment of Systemic Sclerosis

, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RevimmuneTM, the company's proprietary system-of-care based on high-dose administration of Cytoxan(R) (), for the treatment of two...

» Report on the 2010 Systemic Sclerosis World Congress

Robert J. Riggs, CEO of the recently reported on his experience at the recently concluded , held in Florence, Italy. Here's a brief excerpt. In February, I attended the 1st World Congress on Systemic Sclerosis in Florence, Italy. The three-day...

» Targeting Systemic Sclerosis: From Bioinformatics to Clinical Research

Systemic sclerosis (SSc), also known as Scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Dartmouth's Geisel School of Medicine and Northwestern University's Feinberg School of...

» Clinical Significance of Antibodies to Ro52/TRIM21 in Systemic Sclerosis

Marie Hudson, Janet Pope, Michael Mahler, Solene Tatibouet, Russell Steele, Murray Baron, Canadian Scleroderma Research Group (csrg) and Marvin J FritzlerArthritis Research & Therapy 2012, 14:R50 doi:10.1186/ar3763Published: 6 March...

» Researchers Identify Core Genetic Switch As A Viable Target For New Scleroderma Treatments

Scleroderma is a rare, autoimmune disease. Often fatal, it causes the fibrosis or thickening of the connective tissue which support the skin and other vital organs within the body, through the overproduction of . The disease currently lacks a cure...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh